Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase II study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase II clinical study for treating patients with acute myocardial infarction; and, which is in Phase I/II clinical study for treating patients with acute respiratory distress syndrome, as well as that has completed Phase I clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke in Japan; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone216-431-9900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.71 million
Profitability
Miscellaneous
Employees66
OptionableOptionable
Athersys (NASDAQ:ATHX) Frequently Asked Questions
What is Athersys' stock symbol?
Athersys trades on the NASDAQ under the ticker symbol "ATHX."
How were Athersys' earnings last quarter?
Athersys, Inc. (NASDAQ:ATHX) issued its quarterly earnings data on Tuesday, November, 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. The biopharmaceutical company earned $2.32 million during the quarter, compared to analyst estimates of $1.80 million. Athersys had a negative return on equity of 58.74% and a negative net margin of 108.83%. View Athersys' Earnings History.
When is Athersys' next earnings date?
What price target have analysts set for ATHX?
1 Wall Street analysts have issued 12 month price objectives for Athersys' shares. Their predictions range from $6.00 to $6.00. On average, they anticipate Athersys' stock price to reach $6.00 in the next year. This suggests a possible upside of 319.6% from the stock's current price. View Analyst Price Targets for Athersys.
What is the consensus analysts' recommendation for Athersys?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Athersys.
What are Wall Street analysts saying about Athersys stock?
Here are some recent quotes from research analysts about Athersys stock:
- 1. According to Zacks Investment Research, "Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an off the shelf allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD). " (1/16/2019)
- 2. Maxim Group analysts commented, "Athersys reported 2Q18 with $19.4M in revenue, which includes $18.5M related to the expanded partnership with Helios (6927JP – NR). With operating expenses just over $12M, the company ended the period with net income of $6.9M, as well as $53.4M in cash on the balance sheet." (8/8/2018)
Has Athersys been receiving favorable news coverage?
Press coverage about ATHX stock has trended positive on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Athersys earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future.
Who are some of Athersys' key competitors?
Some companies that are related to Athersys include Athenex (ATNX), Radius Health (RDUS), Y-mAbs Therapeutics (YMAB), Principia Biopharma (PRNB), ImmunoGen (IMGN), Epizyme (EPZM), Dynavax Technologies (DVAX), CytomX Therapeutics (CTMX), G1 Therapeutics (GTHX), AC Immune (ACIU), Urogen Pharma (URGN), Rocket Pharmaceuticals (RCKT), Intra-Cellular Therapies (ITCI), Dicerna Pharmaceuticals (DRNA) and Eagle Pharmaceuticals (EGRX).
Who are Athersys' key executives?
Athersys' management team includes the folowing people:
- Dr. Gil Van Bokkelen, Co-Founder, Chairman & CEO (Age 57)
- Mr. William B. J. Lehmann Jr., Pres, COO & Sec. (Age 52)
- Dr. John J. Harrington, Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 51)
- Ms. Laura K. Campbell, Sr. VP of Fin. (Age 54)
- Dr. Manal Morsy M.D., PH.D., Sr. VP & Head of Global Regulatory Affairs
How do I buy shares of Athersys?
Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Athersys' stock price today?
One share of ATHX stock can currently be purchased for approximately $1.43.
How big of a company is Athersys?
Athersys has a market capitalization of $202.70 million and generates $3.71 million in revenue each year. The biopharmaceutical company earns $-32,240,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Athersys employs 66 workers across the globe.
What is Athersys' official website?
How can I contact Athersys?
Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]
MarketBeat Community Rating for Athersys (NASDAQ ATHX)
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe ATHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
